Egypt's Eastern Tobacco Company posts 17 % increase in its net profit in 7 months    NBE: Exchange rates of key global currencies rates Thursday 25-02-2021 vs. Egyptian pound    Egyptian prominent businessman Hussein Sabbour dies at age of 85    Egypt sends new batch of medical, food aid to Lebanon    Queensland may build new stadium if 2032 Olmypics bid successful: Official    US Capitol Police quickly overwhelmed by 'insurrectionists' on 6 January, acting chief says    Egypt's Sisi ratifies joining customs convention on international trade    UPDATED: India and Pakistan agree to stop cross-border firing in Kashmir    Mendy fires late winner as Real struggle to beat 10-man Atalanta    Portuguese connection sparks City's 2-0 win v Gladbach in CL    Egypt detects 644 new coronavirus infections; 52 fatalities on Wednesday    Jordan extends night curfew after wide spread of British virus strain    Turkish pilots, official get 4-year jail over Ghosn escape    Egypt's PM orders formation of committee to facilitate registration of real estate    India warns states of worsening COVID-19 situation if rules ignored    Egyptians can register for COVID-19 vaccine next Sunday    Eschewing the radical    Senate prepares for its first session    Cairo theatres programme: 25 February - 3 March 2021    Diversified and at eye-level: German-Egyptian archaeological cooperation    Egypt's Sarwa Insurance partners with Hannover Re to offer COVID-19 related travel insurance    Tales of the city    Mohamed Bazoum solidifies lead in Niger's presidential election runoff    Egypt to receive 300,000 doses of China Sinopharm's COVID-19 vaccine tonight    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Russian flights to return to Sharm el-Sheikh and Hurghada for first time since 2015    Australia slams Facebook's move to block news as unnecessary and heavy-handed    Sisi calls on securing fair access to coronavirus vaccines for African nations    Egypt eyes gradual return for tourism after revenues fall to $4 bln in 2020    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Nassef Sawiris plans to up his stake in owner of New York Knicks, Rangers    Cairo International Book Fair suspended for five months over coronavirus concerns    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Global Finance: Egypt's Tarek Amer among the world's top 20 central bank governors    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    

Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.

BREAKING: Moderna coronavirus vaccine almost 95% effective; early trial shows
Published in Amwal Al Ghad on 16 - 11 - 2020

Moderna Inc announced on Monday its coronavirus vaccine candidate was 94.5 percent effective, becoming the second U.S. company after Pfizer to add growing confidence that vaccines can help end the pandemic.
The news comes a week after Pfizer and BioNTech said their vaccine was more than 90 percent effective.
The results for both Moderna and Pfizer- BioNTech vaccines come from interim analyses of large clinical studies.
In the Moderna study there were 30,000 volunteers, of which half got two doses of the vaccine 28 days apart, and the other half had two shots of a placebo on the same schedule.
The results indicate the vaccine was inducing the kind of immune response that protects people if they were exposed to the coronavirus, the company added.
"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," Stéphane Bancel, chief executive officer of Moderna, said in a statement.
Both the Moderna and Pfizer vaccines are using the same technology to make their vaccines. This technology is based on a molecule known as mRNA, or messenger RNA, which contains genetic instructions for making proteins inside cells.
The Moderna and Pfizer- BioNTech studies were conducted using slightly different protocols. To be counted as a coronavirus case, participants in the Moderna study had to have at least two symptoms of disease along with a positive test for the virus.
In the Pfizer- BioNTech study, it is required only one symptom.
Also, Moderna waited 14 days following the second injection to begin counting cases, while Pfizer- BioNTech study started counting at seven days.
Another difference in the two vaccines is that both differ in their storage requirements.
Moderna said its vaccine can be safely stored in freezers at around 25 degrees Fahrenheit (-4 degrees Celsius), a temperature easily reached by a home refrigerator freezer.
Pfizer- BioNTech vaccine required storage in specialised ultracold freezers capable of cooling below -94 degrees Fahrenheit (-70 degrees Celsius).
Moderna also said its vaccine would remain potent for up to 30 days at normal refrigerated temperatures, which should ease distribution.
Pfizer and Moderna are still gathering safety data required by the U.S. Food and Drug Administration (FDA) to get an emergency use authorisation that would allow the companies to distribute the vaccine during the pandemic.
For Moderna vaccine, side effects seen at the interim analysis included pain at the injection site, fatigue, and aching muscles and joints. Its data safety and monitoring board did not identify "any significant safety concerns."
Moderna said it plans to file "in the coming weeks" with the FDA for authorisation of the its vaccine for emergency use.
The drugmaker added that it expects to be able to ship about 20 million vaccine doses in the U.S. by the end of 2020. Next year, it said it expects to be able to make 500 million to 1 billion doses worldwide.

Clic here to read the story from its source.